Intrexon to acquire ERC specialist Medistem for $19.5mm in cash and stock
Intrexon Corp. (biological enabling platforms) acquired publicly traded regenerative medicine company Medistem Inc., which specializes in endometrial regenerative cells (ERCs), for $19.5mm in cash and stock (in the event of a share split, the deal value is not to exceed $26mm). For each of Medistem’s 14.4mm outstanding shares, stockholders received $0.27 in cash and $1.08 of an Intrexon share (approximately 0.54 of a share), equating to a 39% premium.
- Gene Therapy, Cell Therapy
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.